Capstone expects positive adjusted EBITDA in Q2 2026

Capstone Holding Corp

Capstone Holding Corp

CAPS

0.00
  • Capstone Therapeutics forecast positive Adjusted EBITDA for Q2 2026 following integration gains from recent acquisitions.
  • Converted $700,000 of surplus inventory into full-margin sales within six months of the Canadian Stone Industries deal.
  • Integration platform redeployed inventory to higher-demand markets, supporting working-capital efficiency and margin expansion.
  • Midwest distribution network consolidation in May targeted $500,000 in annualized cost savings, unlocking $700,000 of working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607140730BIZWIRE_USPR_____20260714_BW176416) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.